Karen Reckamp, MD, MS

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Karen Reckamp, MD, MS sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting early-phase tilt upper half by trial count

Karen Reckamp, MD, MS: 1 sponsored US clinical trial, 1 recruiting.

Karen Reckamp, MD, MS sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lung Cancer, with 1 trials.

Mid-pack sponsor footprint

Karen Reckamp, MD, MS is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING Phase 1

Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

NCT05401110

Phase Distribution

PhaseTrial count
Phase 1 1

Therapeutic Areas

Lung Cancer 1
Non-Small Cell Lung Cancer 1

What is open in the Karen Reckamp, MD, MS pipeline

1 recruiting of 1 indexed (100% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Lung Cancer (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Karen Reckamp, MD, MS: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Karen Reckamp, MD, MS sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Karen Reckamp, MD, MS1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Karen Reckamp, MD, MS sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Karen Reckamp, MD, MS sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Karen Reckamp, MD, MS page

1 registered trials is a research-attention snapshot, not an endorsement of Karen Reckamp, MD, MS or any single study.

  • 1 of Karen Reckamp, MD, MS's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Lung Cancer is the condition Karen Reckamp, MD, MS studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lung Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Karen Reckamp, MD, MS pipeline card: 1 registered trials from official public datasets.Report a data error.